Trial Profile

Phase 1/2 trial of HB-300 for the treatment of metastatic castration-resistant prostate cancer

Status: Suspended

Phase of Trial: Phase I/II

Latest Information Update: 01 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

29 Jan 2024 Status changed from recruiting to suspended, according to a Hookipa Pharma media release.
29 Jan 2024 According to a Hookipa Pharma media release, the company to pause further development of its HB-300 to conserve capital and ensure pipeline success and operational efficiency.
11 May 2023 According to a Hookipa Pharma media release, the company announced the acceptance of a trial-in-progress presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com